Launch Momentum Tonix launched TONMYA on January 1, 2026, marking the first fibromyalgia therapy approved in more than 15 years. The company posted Q1 2026 revenue growth driven by TONMYA and stronger migraine product sales, signaling strong early commercial momentum and an opportunity to expand the field force to neurology, pain management, and related specialties with cross-sell potential to patients treated for migraines.

Payer Value A large share of fibromyalgia patients carry comorbidities and incur substantial inpatient costs, creating a compelling case for TONMYA to deliver long-term cost savings. Use retrospective analyses and real-world data to support payer coverage and hospital adoption, and develop access programs to accelerate formulary inclusion and patient access.

Psychiatric Expansion Tonix is evaluating TONMYA in major depressive disorder and acute stress disorder (Phase 2). This expansion offers sales opportunities to reach psychiatrists, behavioral health clinics, and primary care providers who manage mood symptoms and central sensitization, leveraging existing CNS channels to grow the addressable market.

Immunology Opportunities TNX-4800, a long-acting anti-OspA monoclonal antibody for Lyme disease prevention, presents partnership opportunities with tick-borne disease prevention programs, travel and outdoor medicine clinics, and hospital vaccination networks. TNX-1500 targeting kidney transplant rejection suggests outreach to transplant centers and organ networks for early adopters within immunology and transplant therapeutics.

Partnership Potential Tonix’s pipeline includes TNX-2900 for Prader-Willi syndrome (Phase 2 ready) and TNX-102 SL for central sensitization, signaling opportunities for co-development, licensing, or distribution deals with larger pharma to accelerate commercialization in rare diseases and immunology, expanding the company’s BD outreach.